BCL
Showing 1 - 25 of 778
Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- +8 more
- Biospecimen Collection
- +3 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Mar 8, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (BP1002; Liposomal Bcl-2 Antisense
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- Decitabine (in combination with BP1002)
- (no location specified)
Mar 8, 2022
Endometrial Carcinoma Cellular Diagnosis Trial (1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2
Completed
- Endometrial Carcinoma Cellular Diagnosis
- 1.hysterectomy with bilateral oophorectomy and pelvic lymphonodectomy. 2 explorative curettage
- (no location specified)
Jul 16, 2023
Prostate Cancer Trial in Herlev (Bcl-Xl_42-CAF09b vaccine)
Completed
- Prostate Cancer
- Bcl-Xl_42-CAF09b vaccine
-
Herlev, DenmarkHerlev Hospital
Jan 10, 2022
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent
Not yet recruiting
- Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
- +21 more
- Biopsy
- +8 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 7, 2023
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston
Recruiting
- Mantle Cell Lymphoma
- +9 more
- L-Bcl-2 antisense oligonucleotide
-
Augusta, Georgia
- +2 more
Nov 18, 2022
Laryngeal Cancer Trial in Ann Arbor (AT-101, Docetaxel, Cisplatin)
Completed
- Laryngeal Cancer
- AT-101
- +3 more
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Dec 17, 2021
Breast Tumor Female Trial in Melbourne (Venetoclax, Palbociclib, Letrozole)
Recruiting
- Breast Neoplasm Female
- Venetoclax
- +2 more
-
Melbourne, Victoria, Australia
- +2 more
Mar 10, 2022
Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory Trial
Not yet recruiting
- Waldenstrom Macroglobulinemia
- +2 more
- (no location specified)
Jul 18, 2023
Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between
Not yet recruiting
- Recurrent ALK Positive Large B-Cell Lymphoma
- +28 more
- Biospecimen Collection
- +5 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 17, 2022
Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma
Not yet recruiting
- Double-Expressor Lymphoma
- +3 more
- Cyclophosphamide
- +6 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 27, 2022
Persistent Epithelial Defect Trial in Monterrey (PRP plus BCL, BCL plus PFL, Eye patch plus ocular lubricant ointment)
Recruiting
- Persistent Epithelial Defect
- PRP plus BCL
- +2 more
-
Monterrey, Nuevo Leon, MexicoDepartamento de Oftalmologia, Hospital Universitario "Dr. Jose E
May 16, 2022
ALK-Positive Large B-Cell Lymphoma, Burkitt-Like Lymphoma With 11q Aberration, DLBCL Activated B-Cell Type Trial in United
Active, not recruiting
- ALK-Positive Large B-Cell Lymphoma
- +34 more
- Nivolumab
- Varlilumab
-
Phoenix, Arizona
- +32 more
Jan 3, 2023
Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)
Recruiting
- Acute Myeloid Leukemia
-
Beijing, Beijing, ChinaPeking University People's Hospital
Jun 23, 2023
Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial (LP-108, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- +2 more
- (no location specified)
Nov 29, 2022
Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by
Active, not recruiting
- Non Hodgkin Lymphoma
- +4 more
- DA-EPOCH-R followed by Nivolumab
-
Antwerpen, Belgium
- +23 more
Mar 23, 2022
Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma Trial (Biopsy, Biospecimen
Not yet recruiting
- Metastatic Endometrial Carcinoma
- +7 more
- Biopsy
- +5 more
- (no location specified)
Jan 18, 2023
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)
Active, not recruiting
- T-Cell Lymphoma Relapsed
- T-Cell Lymphoma Refractory
-
Aviano, Italy
- +12 more
Dec 20, 2022
Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Decitabine for Injection
- VENCLYXTO
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023
Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6
Withdrawn
- Recurrent Diffuse Large B-Cell Lymphoma
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 11, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma Trial in Shanghai (BCL2 Inhibitor plus IM2 regimen)
Recruiting
- T-lymphoblastic Lymphoma
- +5 more
- BCL2 Inhibitor plus IM2 regimen
-
Shanghai, Shanghai, ChinaShanghai General hospital,Shanghai Jiao Tong University School o
Jan 10, 2023